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Abstract: The importance of reactive oxygen species (ROS) has been gradually acknowledged over
the last four decades. Initially perceived as unwanted products of detrimental oxidative stress,
they have been upgraded since, and now ROS are also known to be essential for the regulation of
physiological cellular functions through redox signaling. In the majority of cases, metabolic demands,
along with other stimuli, are vital for ROS formation and their actions. In this review, we focus on the
role of ROS in regulating cell functioning and communication among themselves. The relevance of
ROS in therapy concepts is also addressed here.
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1. Introduction
The understanding of the role of reactive oxygen species (ROS) in our cellular functioning has
changed over the last few decades, from the first perception of ROS as harmful and unwanted
byproducts of oxidative stress [1] (something else formerly considered to be unwanted) to realizing
their significance in redox signaling. The notion of oxidative stress as a harmful process leading to the
formation of ROS has since been upgraded, and different subclasses of oxidative stress are generally
classified into eustress and distress [2,3]. The formation of lower levels of ROS that act as redox
signaling messengers needed for the normal physiological functioning of cells is denoted as good
stress, or eustress. In contrast, the overwhelming accumulation of ROS manifested as a loss of signaling
ability and unspecific damage of cellular macromolecules which contributes to different pathologies
is denoted as bad stress, or distress. Hence, the consideration of antioxidants as “defenders” that
are able to amend these harmful ROS-induced events emerged. Unfortunately, clinical data has not
supported this notion due to controversy regarding the obtained results, suggesting that redox-sensitive
pathophysiology needs further research. The current knowledge addressing these issues was recently
comprehensively reviewed by the Cost Action BM1203 (EU ROS) members [4]. Therefore, a better
understanding of both terms, especially eustress, regarding ROS-specific targets and the conditions in
which they occur is a constant pursuit in the field of redox biology. The answers to the raised questions
would also improve our knowledge of clinically reliable biomarkers of oxidative stress [5].
In this short review, we endeavor to highlight the importance of ROS in cellular functioning within
each cell and among them, which is intertwined with metabolism and therefore cell/tissue specific. We
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further explore the notion that ROS are messengers in the transduction of certain cues (e.g., metabolic
and environmental) involving ROS-activated transcription factors and other proteins, thus affecting
diverse signaling pathways which, ultimately, determine cell fate. Our aim is to point out that cells,
depending on the cues, reorganize their processes, mainly metabolism, to produce ROS that, because
they are signaling molecules, will thereby affect cell fate. In this way, we highlight ROS as instruments
and tools that enable cells and tissues to function thus as regulators of cell fate rather than as signaling
molecules. Additionally, the ROS-related actions of some drugs and therapy strategies are mentioned.
2. ROS Sources and Functions
Oxygen, which is essential for life, is also, to some minor extent, converted to ROS. The most
common representatives of ROS are superoxide anions, hydrogen peroxide, and hydroxyl radicals,
in addition to many others. Diverse intracellular sources such as mitochondria, NADPH
(nicotinamide adenine dinucleotide phosphate) oxidases (NOX), cytochrome P450, endoplasmic
reticulum, peroxisomes, lysosomes, and others produce ROS [6]. Exogenously, ROS are also formed
under the influence of ultraviolet light, ionizing radiation, and xenobiotics [7] (Figure 1). As mentioned,
ROS are both essential for normal cellular functioning but also detrimental if produced in excess
(the amount considered excessive is cell/tissue-type specific and depends on the specific ROS that
accumulate; e.g., the hydroxyl radical is the least tolerable due to its high damaging ability).
To cope with elevated levels of ROS, cells have evolved antioxidative machinery comprising
enzymes and nonenzymatic antioxidants (e.g., glutathione (GSH), uric acid, melatonin, vitamins C and
E, polyphenols, etc.) [7,8]. Enzymes involved in the first line of defense against ROS include superoxide
dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX) (Figure 1). SOD catalyzes the
conversion of superoxide anions to hydrogen peroxide, which can be further reduced to water in a
reaction catalyzed by CAT or by GPX. The reaction involving GPX requires oxidation of GSH and
the formation of glutathione disulfide (GSSG), which is reduced back again to GSH by glutathione
reductase [9,10]. Yet, the presence of trace metals can catalyze the formation of more destructive
hydroxyl radicals from hydrogen peroxide via the Fenton reaction (Figure 1). Therefore, the production
of ROS is in delicate balance with the described antioxidative defense mechanisms. If this balance is
disturbed, the accumulation of ROS could become detrimental, leading to diverse pathologies such as
neurodegenerative diseases [11], atherosclerosis [12], cancer [13], and others.
Redox signaling, as a term, mainly includes reversible modification, either oxidation or covalent
adduct formation, of specific target proteins, allowing further translation of a signal which will
ultimately determine cellular fate. Cysteine residues are the most susceptible to oxidation. Yet, notably,
not all cysteine residues of a target protein are susceptible to modification but rather specific ones.
Location (vicinity to ROS) and kinetics determine their specificity [14]. While signaling abilities of
superoxide anions and hydroxyl radicals are considered modest or even nonexistent due to the lower
stability and unspecific reactivity, respectively, hydrogen peroxide is depicted as the most important
signaling molecule involved in redox signaling (additional reading suggestions [13,15,16]).
Better stability and the ability to pass through cellular membranes, thus diffusing away from its
place of origin, ensure the superiority of hydrogen peroxide compared with, for example, superoxide
anion. The fine-tuning of hydrogen peroxide levels within and between cells and extracellular
space requires efficient transport across the membrane. Among a family of transmembrane water
channels, named aquaporins, specific isoforms (“peroxiporins”) are responsible for hydrogen peroxide
transport [17–19]. Yet, redox biology is rather complex and, also, other molecules contribute to redox
signaling, such as hydroperoxides [14], 4-hydroxynonenal (HNE; ROS-induced lipid peroxidation
product) [20], as well as peroxiredoxins and thioredoxins, exhibiting not merely an antioxidant role [21].
In addition, many target proteins (such as several kinases, transcription factors, phosphatases, etc.)
are involved in redox signaling [22]. Therefore, the causally consequential interplay between ROS (as
well as other messenger molecules) and metabolism ensures tight regulation of redox signaling, thus
controlling cellular functions, from proliferation to differentiation and apoptosis.
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Figure 1. Generation of reactive oxygen species (ROS) and their impact on cells. This is a simplified
scheme representing exogenous (e.g., UV light, ionizing radiation, pharmaceuticals, etc.) and
endogenous sources (e.g., electron transport chain in mitochondria, NADPH (nicotinamide adenine
dinucleotide phosphate) oxidases, peroxisomes, endoplasmic reticulum, etc.) of ROS formation.
Cells have evolved antioxidative mechanisms (e.g., glutathione (GSH), superoxide dismutase (SOD),
catalase (CAT), glutathione peroxidase (GPX), etc.) that fine-tune ROS levels, ensuring normal cellular
functioning. Thus, depending on the levels, ROS affect different transcription factors, enzymes, and/or
other proteins, inducing signaling pathways that assure proper functioning and, in general, health.
In contrast, higher levels of ROS lead to irreversible damage of macromolecules, thus eventually
leading to disease. Again, depending on the levels, ROS impact cellular functions such as proliferation,
differentiation, and apoptosis.
Diverse signaling pathways are activated by ROS, thus determining cellular fate (see [9,23]).
ROS activates the NRF2/KEAP1 (nuclear factor erythroid 2 (NF-E2)-related factor 2/Kelch-like
ECH-associated protein 1) pathway, which serves as a master regulator of ROS levels. In particular,
ROS-induced modification of specific cysteine residues of KEAP1 occurs, leading to disruption of
the KEAP1-dependent degradation of NRF2, translocation of NRF2 to the nucleus, and its activation
of specific cytoprotective genes [15,24]. Additional pathways regulated by ROS include nuclear
factor-κB (NF-κB; of significance in inflammation and immunity) [25,26], phosphoinositide 3-kinase
(PI3K)/AKT [27], MAPK (mitogen-activated protein kinase), as well as others [23]. Therefore, depending
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on the stimuli, ROS activate diverse targets, initiating pathways involved in growth promotion and
survival (including autophagy) [28] or apoptosis [29].
3. Cell/Tissue-Specific Roles of ROS in (Patho)physiology
The importance of ROS in the functioning of diverse cell types and, consequently, in tissues is
immense. Here, we provide just a few examples that highlight ROS as important regulators/cellular
tools for reaching specific cell/tissue functions. The recent notion of ROS-directed evolutionary
advances of multicellular organisms substantiates this claim. Its main feature is the formation of
cytoskeleton-based membrane protrusions that enable intercellular communication and transport of
macromolecules [30]. Therefore, ROS not only guide tissue maintenance, but they are also important
in the earliest phases of embryonic development starting from fertilization [31,32], as it seems that
calcium signaling induces the formation of ROS either by activation of Udx1, a dual NOX [33], or in
mitochondria [34], which then blocks polyspermy and directs zygote cleavage.
3.1. Stem Cells
Stem cells are important for embryonal and fetal development and in the maintenance of adult
tissue homeostasis. Their main features are self-renewal and differentiation into various types of cells,
the potential of which depends upon the type of stem cell. Whether stem cells will remain quiescent or
progress to self-renewal or differentiation is strongly affected by metabolic changes. These changes
are, in a feedback loop, governed by ROS that through activation of various but stimuli-specific target
proteins, such as transcription factors, kinases, and phosphatases, further orchestrate cellular processes,
thus regulating cell cycle progression (proliferation or arrest), differentiation, quiescence, senescence, or
apoptosis [35]. Therefore, ROS were proposed to function as a stem cell rheostat, translating different
cues (metabolic and environmental) to coordinate various cellular responses [36]. To which cellular
process ROS will direct a stem cell is highly stem-cell-type specific and intertwined with metabolism.
For example, self-renewal in embryonic stem cells is a rapid process due to the shortened G1 cell cycle
phase. For that reason, it needs much energy and many building blocks, which are preferentially
achieved by glycolysis and the pentose phosphate pathway (PPP), respectively [37]. Of note is the fact
that different stem cells vary in ROS levels. While a low level of ROS selects more potent hematopoietic
stem cells [38], accumulation of ROS controls proliferation and self-renewal in neuronal stem cells [39].
In mesenchymal stem cells, ROS seem to have a double role. Although the undifferentiated state is
correlated with lower levels of ROS and the buildup of antioxidative enzymes, mesenchymal stem
cells need to upregulate ROS for proliferation and self-renewal [40]. A recent review paper focusing on
the cell fate decisions of different types of stem cells emphasized the importance of metabolism, ROS,
pH, as well as cell morphology and highlights—indeed, that “the link between the metabolic cue and
the cell fate decision is reactive oxygen species” [41].
3.2. Immune Cells
The primary role of immune cells is the defense of the host organism against infection induced by
invading pathogens. Different types of cells mediate this defense with distinct responses. Phagocytic
cells (mainly neutrophils and macrophages) are engaged in an innate immunity response which is
nonspecific, while lymphocytes mediate an adaptive immune response. ROS are important for both
innate and adaptive immunity [9]. The first beneficial role described attributed to the generation
of ROS was phagocytic elimination of microorganisms. Phagocytic recognition of a specific pattern
of a microorganism initiates NOX2 production of ROS that will ultimately kill this microorganism.
Convincingly, patients suffering from chronic granulomatous disease (CGD) have a heightened
susceptibility to infection due to the mutations in NOX2 [42]. ROS were also suggested not only to
coordinate the movement of the polymorphonuclear leukocytes towards pathogens and their retention
at the site during initiation of inflammation but also to terminate inflammation [43]. In adaptive
immunity, ROS mediate activation of T cells and have been suggested to have an immunosuppressive
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role. T-cell activation also mandates the help of accessory cells to some extent. Induction of regulatory
T (Treg) cells by macrophage-derived ROS was shown to suppress other T cells also through ROS.
Moreover, localized production of ROS directs the commitment of the Treg lineage, while scavenging
ROS decrease the Treg/T-cell effector balance [43,44].
3.3. Central Nervous System (CNS)
High energy demands, high oxygen consumption, high levels of iron and polyunsaturated fatty
acids, low antioxidative protection, and a delicate blood supply make the CNS, in particular the brain,
an easy target of oxidative damage [45]. ROS have been implicated in many pathological conditions,
such as neurodegenerative disorders, stroke, and brain tumors [46], due to the high levels found,
but their physiological roles have been mainly neglected until recent years.
Inevitably, there is a link between ROS formation and the metabolism of cells. Metabolic processes
in neurons, glial cells, and endothelial cells, although largely different and variable, are complementary
to assure proper functioning of the brain [47]. While oxidative phosphorylation (OXPHOS) is the
primary energy-obtaining pathway in neurons, astrocytes rely mostly on glycolysis. Such conversion
of glucose to lactate also serves as an energy source for neurons in a process known as metabolic
coupling [48]. This fine astrocyte–neuron cooperation includes coordination of glucose metabolism
and antioxidative protection, especially for neurons with diminished levels of antioxidants [49,50].
ROS produced by metabolic processes modulate the physiological processes of neuronal development,
regulation of neuronal polarization, connectivity, and plasticity [51,52]. NOX have been proposed as
the main source of ROS required for regulation of processes in the brain. For example, stemness and
proliferation of neural progenitor cells were shown to be under strict control of NOX2-ROS production
and PI3K/AKT signaling [39]. The premise that ROS are maintenance regulators of neuronal progenitor
cells was also supported by a NOX2 knock-out mouse model, which revealed a decreased number of
proliferating neural stem cells and reduced adult neurogenesis [53].
Recently, mitochondrial ROS emerged as predominant for controlling microenvironmental cues,
highlighting astrocytes as the most sensitive sensors, regulators, and protectants of neural functions.
Higher mitochondrial ROS levels in astrocytes, associated with the more loose organization of
the mitochondrial transport chain [54], are responsible for more robust antioxidative protection.
Vicente-Gutierrez et al. have linked mitochondrial and extracellular ROS production, showing that
these higher physiological mitochondrial ROS levels in astrocytes keep NRF2 constitutively active,
which consequently attenuates NOX1 and NOX2 expression, thus repressing the release of extracellular
ROS. Moreover, mitochondrial ROS-induced NRF2 activity maintains sufficient GSH levels in the
extracellular matrix, allowing astrocytes to oversee the redox balance in neurons [55]. Aside from the
beneficial roles of ROS in the regulation of physiological processes, the excess of ROS that could not
be hampered by antioxidative mechanisms contributes to macromolecular damage and the onset of
various CNS diseases.
3.4. Other Examples of Cell/Tissue-Specific Roles of ROS
In the kidney, ROS are important for regulation of both physiological and pathological processes.
While they are needed for protection and restoration of normal kidney functioning, during kidney
damage, such as ischemia-reperfusion injury, ROS recruit neutrophils and also trigger NRF2 signaling
to bust antioxidative protection (reviewed in [56]). In addition, endothelial NOX2 and NOX4 were
shown to be sources of hydrogen peroxide, which acts as a regulator of the vessel wall tension, thus
ensuring proper functioning of kidney vasculature [57]. Moreover, NOX4-mediated production of
hydrogen peroxide might have an antiatherosclerotic function as well [58].
Another example of an ROS-mediated cell-specific role is platelet generation. It includes different
stages, starting from the commitment of hematopoietic stem cells into the megakaryocytic lineage,
megakaryocytic progenitor proliferation, differentiation and maturation, cell apoptosis, and platelet
release, all regulated by ROS [59]. For instance, the promotion of megakaryocytic maturation requires
Cells 2019, 8, 793 6 of 14
ROS, the regulation of which is under NF-E2 p45 and not NRF2, since it activates antioxidative
machinery to a lesser extent, thus enabling higher ROS levels needed for full activation of platelet
genes [60].
4. ROS in Carcinogenesis
Although the relationship between ROS and cancer has been studied for many years, even
nowadays rising insights contribute to a better understanding of the complex involvement of ROS in
cancer development, as well as in therapies. ROS can affect cellular macromolecules, thus inducing
genomic instability and mutations, thereby implying their role in the initiation of cancer. For example,
a well-established role is in chronic inflammation, where ROS derived by myeloid cells induce
epithelial mutagenesis, thus stimulating invasive growth [61]. In contrast to their procarcinogenic role,
ROS also have an anticarcinogenic role because this genetic instability often elicits additional ROS,
which trigger cell senescence and apoptosis, thus limiting further proliferation of the transformed
cells, which therefore prevents cancer progression [62]. This cancer-suppressive role of ROS is highly
dependent upon the concentration of ROS and can be abolished by antioxidants, thereby confirming
their role in carcinogenesis (Figure 2). Indeed, GSH and thioredoxin, both decreasing levels of ROS
below the ones that would lead to apoptosis, are implicated in different stages of carcinogenesis: GSH
in cancer initiation and thioredoxin in the progression of already-established cancer [63].
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Therefore, the antioxidative machinery boost, either endogenously through activation of the
NRF2-KEAP1 pathway or exogenously by nutritional supplementation, is still highly controversial
and seems to be dependent on the stage of carcinogenesis [7,24,62,64]. The causally consequential
relationship of ROS with genetic, metabolic, and microenvironment-associated alterations occurring in
cancer (Figure 3) has highlighted their importance in almost all hallmarks of cancer (reviewed in [65]).
Here, we focus on the interplay between ROS, metabolic, and microenvironment-associated alterations,
highlighting ROS as instruments/tools produced by cancer cells, exploiting their signaling ability to
the levels contributing to cancer progression. A fine balance of ROS levels and their proximity to a
specific target should be achieved to activate cancer-growth-promoting pathways such as PI3K/AKT,
MAPK (Erk1/2, p38, and JNK), and IKK/NF-κB [66,67].
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hypoxic conditions stabilize and activate HIF 1 [75]. An increase of ROS is also observed during
glucose deprivation, leading to activation of the cellular energy sensor AMPK. The main role of AMPK
is metabolic reprogramming in favor of catabolism while suppressing anabolism to promote cell
survival [76]. AMPK-induced regulation of different metabolic pathways, in a feedback loop, affects
ROS and tunes their levels with NADPH and GSH to those which promote survival of cancer cells [77].
Metastatic advantage upon matrix detachment was linked to Ca2+-ROS signaling network activation
of AMPK [78]. Of note is the dual role of AMPK in carcinogenesis as a promoter of cancer cell survival
under metabolic stress and as a mediator of cancer-suppressive signaling of tumor-suppressor liver
kinase B1 (LKB1), respectively [79,80]. Therefore, ROS mediate metabolic reprogramming through the
activation of HIF 1 and AMPK, which in turn finely tune their levels by the generation of antioxidative
molecules (NADPH and GSH) as well as redox cofactors (NADH and FADH) [81]. In addition, a recent
perspective suggests the metabolic reprogramming, in particular, change from glycolysis to PPP upon
persistent oxidative stress as an additional dedifferentiation step from cancer cells to cancer stem
cells [82].
5. ROS Implications in Therapy
ROS involvement in therapy strategies is best described for anticancer treatments, as most of
the conventional anticancer therapy (chemo- and radiotherapy) is indeed based on excessive ROS
production. In addition, the importance of ROS as a potential therapeutic tool has recently emerged
in the field of regenerative medicine, which aims to heal or replace damaged cells, tissues, or organs.
Therefore, these two strategies are discussed in this section.
5.1. ROS and Anticancer Therapy
While radiotherapy, chemotherapy, and surgery represent the majority of relatively effective
anticancer treatments involving the overproduction of ROS, the use of various nutraceuticals or
synthetically manufactured compounds acting directly as antioxidants or indirectly as activators
of cellular antioxidative mechanisms, mainly the NRF2 pathway, is still a source of controversy in
anticancer therapy [7,24]. The reason lies in the fact that higher levels of ROS induced by conventional
therapies causing cancer cell death might be lowered by antioxidants, consequently promoting the
survival of cancer cells. In addition, mutations in the NRF2 pathway leading to its constitutive activation
were shown to be a protective mechanism in different cancers [83]. To prevent therapeutic drawbacks,
it is vital to reveal the complex cancer-related redox biology considering the cancer heterogeneity,
the stage of the disease, and the metabolic and redox interplay within and between cancer cells as well
as with their microenvironment. It is thus crucial to define in which conditions ROS (which specifically)
affect their targets (what they are) to selectively eliminate cancer cells without affecting normal cells.
Since alterations in metabolic pathways differ among cancer types and are highly dependent upon
cancer stage and heterogeneity, as already mentioned, the majority of conventional therapies exploit
the most common selective feature of cancer cells—higher levels of ROS. Unfortunately, it is not
completely selective and some unwanted side-effects can occur as a result [7,84]. Therefore, current
research recognizes the advantage of combinational therapy over monotherapy. This newer approach
ensures the lower adaptation ability of cancer cells and, due to the lower doses used, reduction of
unwanted side-effects [85]. Keeping in mind that ROS regulate cancer cellular processes, it is important
to find a switch to ROS-induced apoptosis of cancer cells. Therefore, future anticancer strategies
mandate revealing the underlying beneficial mechanisms of some nutraceuticals and other anticancer
compounds, especially concerning the involvement of ROS. For example, triptolide, a diterpenoid
triepoxide lactone isolated from the plant Tripterygium wilfordii Hook F, was shown to induce apoptosis
in glioma cells by the ROS-activated JNK (c-Jun N-terminal kinase) signaling pathway [86]. Another
apoptosis- and autophagy-related role of the traditional Chinese herb chamaejasmine was also linked
with the formation of ROS in osteosarcoma cells [87]. Recently, the mechanism underlying the anticancer
properties of deoxypodophyllotoxin, a naturally occurring flavolignan isolated from Anthriscus sylvestris,
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was investigated. Growth inhibition of prostate cancer cells was linked to mitochondrial ROS-induced
apoptosis and autophagy. However, the promotion of AKT-independent autophagy through ROS
activation of ERK signaling was also suggested as a protective mechanism against cancer cell apoptosis.
Therefore, the authors proposed usage of autophagy inhibitors, which should potentiate the observed
anticancer effects of deoxypodophyllotoxin [88]. The anticancer properties of another plant-derived
component, lambertianic acid, is linked with the induction of apoptosis through ROS-dependent
phosphorylation of liver kinase B1/AMP-activated protein kinase/acetyl-CoA carboxylase signaling [89].
The improvement of known anticancer properties of certain naturally occurring compounds could be
potentiated by synthesis of their analogs. For example, a novel analog of phenethyl isothiocyanate (an
ROS-inducing and selectively cancer-cell-killing compound present in cruciferous vegetables) was
suggested as a more potent ROS-modulating anticancer compound which can eliminate even cancer
stem cells (a population responsible for cancer recurrence and therapy resistance) [90].
5.2. ROS and Regenerative Medicine
Regenerative medicine is an interdisciplinary field oriented to find the best solutions to heal
or replace damaged cells, tissues, or organs in order to restore their normal functions. To do so,
it involves or combines multiple approaches, such as stem cell therapy, gene therapy, tissue engineering,
biomaterials, and nanotechnology. As mentioned in Section 3.1, ROS affect the main features of stem
cells through the activation of diverse signaling pathways. The pharmacological regulation of ROS in
stem cells was therefore suggested as a possibility for regenerative medicine [91]. Biomaterials may be
needed when defects of or damages to the tissues are too great to be restored with cell therapy alone.
These are synthetic or natural materials and are often made of multiple components able to interact
with the biological system. Biocompatibility is a major consideration when designing biomaterials.
Many studies have highlighted the importance of ROS in inflammation and healing, processes in
which they act as chemoattractants and signaling molecules to recruit inflammatory and healing cells.
However, their role in the biocompatibility of implanted materials may also be significant [92,93]. Since
both cells and biomaterials produce ROS and are influenced by them, oxidative stress was suggested to
be their most direct route of communication [92]. Oxidative stress and lipid peroxidation were shown
to be activated as a growth-promoting signal in osteoblast-like cells in bioactive glasses skeletal-defect
therapy [94,95]. In a recent study, modulation of the mentioned growth-promoting signal with vitamins
was suggested to be beneficial for hydroxyapatite-based materials [96].
6. Conclusions and Future Directions
The role of ROS in physiology as well as in pathology is inevitable. Aside from their contribution
to the onset of disease, when present in excess, ROS determine cellular fate, acting as signaling
molecules. Not all ROS are involved in redox signaling. Hydrogen peroxide is the prominent one,
but other redox messengers are involved as well. They include HNE, hydroperoxides, and thiol
peroxidases [14,20]. Cellular functioning depends upon the translation of ROS-mediated messages
through operating systems (target proteins) into a cell fate decision. Levels of ROS, sources of their
generation, the vicinity of a target protein, and the reaction kinetics determine their redox signaling
potential. NOX and, in particular, mitochondria, due to their ability to dynamically move closer to their
targets, are suggested as the main sources of physiologically relevant ROS [9,97]. In addition, a recent
suggestion that ROS-mediated cysteine modifications have broader regulatory functions substantiates
ROS importance in cellular functioning [98].
Depending on the levels present, ROS switch on and off diverse signaling pathways, thus
affecting all cellular processes, from proliferation to differentiation and apoptosis. This ROS-mediated,
health-oriented regulation contributes to tissue development, normal functioning, and repair.
Unfortunately, in diseases such as cancer, the growth-inducing properties of ROS are exploited by cancer
cells. Of note, a novel mechanism has linked HNE inactivation of cancer-specific membrane-associated
CAT with the subsequent increase of ROS and selective induction of apoptosis in cancer cells [99].
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In this review, our aim was not only to state the importance of ROS in health and disease (focusing
on cancer) but also to highlight the role of ROS in the regulation of how cells function within and
between themselves. A close and intertwined connection of antioxidative machinery and metabolism
is responsible for the fine-tuning of ROS and the elicitation of ROS-specific actions that also affect them.
Thus, depending on the stimuli, cells exploit ROS signaling ability to activate specific pathways that
will determine their fate.
Therefore, future research should focus not only on ROS-specific targets but also on their feedback
loops with antioxidative mechanisms, other signaling molecules, and metabolic fingerprint in a
cell/tissue-specific manner. In a disease state, the stage of the disease and cellular heterogeneity, as well
as ROS involvement in therapeutic approaches, should be stressed to yield a better understanding of
ROS involvement in physiology and pathology. Future findings should elucidate whether ROS are key
regulators of cellular functions, factors affecting their formation and action, and the extent to which
they can be manipulated. The understanding of these aspects might influence future therapy progress.
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